Literature DB >> 183306

Studies of the thromboplastic effect of human plasma lipoproteins.

H Sandberg, L O Andersson.   

Abstract

Human plasma lipoprotein fractions were prepared by flotation in the ultracentrifuge. Addition of these fractions to platelet-rich, platelet-poor and platelet-free plasma affected the partial thromboplastin and Stypven clotting times to various degrees. Addtion of high density lipoprotein (HDL) to platelet-poor and platelet-free plasma shortened both the partial thromboplastin and the Stypven time, whereas addition of low density lipoprotein and very low density lipoprotein (LDL + VLDL) fractions only shortened the Stypven time. The additions had little or no effect in platelet-rich plasma. Experiments involving the addition of anti-HDL antibodies to plasmas with different platelet contents and measuring of clotting times produced results that were in good agreement with those noted when lipoprotein was added. The relation between structure and the clot-promoting activity of various phospholipid components is discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 183306

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro: two procoagulant activities are produced by peripheral blood mononuclear cells.

Authors:  B S Schwartz; G A Levy; L K Curtiss; D S Fair; T S Edgington
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

2.  Isolation and characterization of lipid-protein particles containing platelet factor 3 released from human platelets.

Authors:  H Sandberg; L O Andersson; S Höglund
Journal:  Biochem J       Date:  1982-04-01       Impact factor: 3.857

3.  Interaction of factor VIII-von Willebrand Factor with phospholipid vesicles.

Authors:  L O Andersson; J E Brown
Journal:  Biochem J       Date:  1981-10-15       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.